Piotr Wysocki: 18F-PSMA-PET/CT beats multiparametric MRI in staging high-risk and intermediate-risk prostate cancers
Piotr Wysocki recently posted on LinkedIn:
“Mookerji N et al. conducted a phase 2 prospective study to assess the accuracy of fluorine-18 PSMA-1007 PET/CT (PET/CT-PSMA) compared to multiparametric MRI in staging intermediate-risk and high-risk prostate cancers. The study was conducted at two tertiary care hospitals in Alberta, Canada, in patients with intermediate or high-risk (histopathologically-confirmed) prostate cancer within 2 weeks before radical prostatectomy.
Of 150 eligible men, 134 underwent radical prostatectomy. PSMA PET outperformed MRI in identifying:
- the final tumor stage (45% vs 28%; P = .003)
- dominant nodule (94% vs 83%; P = .01)
- laterality (64% vs 44%; P = .001)
- extracapsular extension (75% vs 63%; P = .01)
There was no significant difference for seminal vesicle invasion (91% vs 85%; P = .07).”
Authors: Nikhile Mookerji, Tyler Pfanner, Amaris Hui, Guocheng Huang, Patrick Albers, Rohan Mittal, Stacey Broomfield, Lucas Dean, Blair St Martin, Niels-Erik Jacobsen, Howard Evans, Yuan Gao, Ryan Hung, Jonathan Abele, Peter Dromparis, Joema Felipe Lima, Tarek Bismar, Evangelos Michelakis, Gopinath Sutendra, Frank Wuest, Wendy Tu, Benjamin A Adam, Christopher Fung, Alexander Tamm and Adam Kinnaird.
Source: Piotr Wysocki/LinkedIn
Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.
His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.
Read other posts by Piotr Wysocki published on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023